Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus

Completed · Phase 1

Conditions studied: Type 2 Diabetes Mellitus

In brief

The purpose of this study is to determine whether administration of AZD1656 will affect the pharmacokinetics of Pioglitazone and vice versa in patients with Type 2 Diabetes Mellitus.

Key facts

Study ID

NCT01082120

Run by

AstraZeneca

People needed

28

Starts

2010-02-01

Expected to finish

2010-05-01

Last updated by the study team

2010-07-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with confirmed Type 2 Diabetes Mellitus for at least 1 year and treated with metformin alone or metformin and one other oral anti-diabetic drug
• Body mass index between ≥19 and ≤42 kg/m2.

You may not qualify if…

• Impaired renal function
• Clinically significant illness or clinically relevant trauma.

Where it is running

• Research Site — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.